Top

BMC Endocrine Disorders

Published in:

Open Access 01-12-2019 | Research article

Vitamin-D2 treatment-associated decrease in 25(OH)D3 level is a reciprocal phenomenon: a randomized controlled trial

Authors: Muhammad M. Hammami, Kafa Abuhdeeb, Safa Hammami, Ahmed Yusuf

Published in: BMC Endocrine Disorders | Issue 1/2019

Abstract

Background

Vitamin-D2 (D2) treatment has been associated with a decrease in 25-hydroxy (25(OH)) vitamin-D3 (D3) level, suggesting that D3 treatment would be preferred to raise total 25(OH) vitamin-D (D) level. We postulated that D2 treatment-associated decrease in 25(OH)D3 level is related to the increase in 25(OH)D level rather than being D2-specific, and thus there would be a similar D3 treatment-associated decrease in 25(OH)D2 level.

Methods

Fifty volunteers were block-randomized to 50,000 IU D2 or placebo orally once (study-1) and fifty volunteers received 50,000 IU D2 orally once and 4 days later block-randomized to 50,000 IU D3 or placebo orally once (study-2). Interventions were concealed from volunteers and research coordinators and blindly-administered. Serum 25(OH)D2 and 25(OH)D3 levels were blindly-determined at baseline and days 14, 28, 42, and 56, post-randomization by high performance liquid chromatography assay. Results of 97 participants were analyzed. Primary outcome measure was day-28 D2-associated change in 25(OH)D3 level in study-1 and D3-associated change in 25(OH)D2 level in study-2, adjusted for baseline levels.

Results

Mean (95% confidence interval) difference between the active and placebo arms in the decrease in day-28 25(OH)D3 (study-1) and 25(OH)D2 (study-2) levels was 13.2 (9.7 to 16.6) and 9.8 (5.2 to 14.4) nmol/L, respectively. Corresponding differences at day-56 were 10.8 (6.8 to 14.8) and 1.7 (− 7.6 to 11.1) nmol/L, respectively. The difference between the placebo and active arms in area-under-the-curve at day-28 (AUC₂₈) and day-56 (AUC₅₆) were 262.3 (197.8 to 326.7) and 605.1 (446.3 to 784.0) for 25(OH)D3 (study-1) and 282.2 (111.2 to 453.3) and 431.2 (179.3 to 683.2) nmol.d/L for 25(OH)D2 (study-2), respectively. There were significant correlations between day-28 changes in 25(OH)D2 and 25(OH)D3 levels in study-1 (rho = − 0.79, p < 0.001) and study-2 (rho = − 0.36, p = 0.01), and between day-28 changes in 25(OH)D2 level and baseline 25(OH)D level in study-2 (rho = − 0.42, p = 0.003).

Conclusions

Compared to placebo, D3 treatment is associated with a decrease in 25(OH)D2 level similar in magnitude to D2-treatment associated decrease in 25(OH)D3 level; however, the D3-placebo difference in 25(OH)D2 level is shorter-lasting. Changes in 25(OH)D2 and 25(OH)D3 levels are correlated with each other and with baseline 25 (OH) D levels, suggesting a common regulatory mechanism.

Trial registration

ClinicalTrial.gov identifier: NCT03035084 (registered January 27, 2017).

Bikle D. Nonclassic actions of vitamin D. J Clin Endocrinol Metab. 2009;94(1):26–34. https://doi.org/10.1210/jc.2008-1454.CrossRefPubMed

Holick MF, Biancuzzo RM, Chen TC, Klein EK, Young A, Bibuld D, Reitz R, Salameh W, Ameri A, Tannenbaum AD. Vitamin D2 is as effective as vitamin D3 in maintaining circulating concentrations of 25-hydroxyvitamin D. J Clin Endocrinol Metab. 2008;93(3):677–81. https://doi.org/10.1210/jc.2007-2308.CrossRefPubMed

Hartwell D, Hassager C, Christiansen C. Effect of vitamin D2 and vitamin D3 on the serum concentrations of 1,25(OH)2D2 in normal subjects. Acta Endocrinol. 1987;115:378–84.CrossRef

Heaney RP, Recker RR, Grote J, Horst RL, Armas LA. Vitamin D(3) is more potent than vitamin D(2) in humans. J Clin Endocrinol Metab. 2011;96(3):E447–52. https://doi.org/10.1210/jc.2010-2230.CrossRefPubMed

Armas LA, Hollis BW, Heaney RP. Vitamin D2 is much less effective than vitamin D3 in humans. J Clin Endocrinol Metab. 2004;89(11):5387–91.CrossRef

Gallo S, Phan A, Vanstone CA, Rodd C, Weiler HA. The change in plasma 25-hydroxyvitamin D did not differ between breast-fed infants that received a daily supplement of ergocalciferol or cholecalciferol for mMonths. J Nutr. 2013;143(2):148–53.CrossRef

Gordon CM, Williams AL, Feldman HA, May J, Sinclair L, Vasquez A, Cox JE. Treatment of hypovitaminosis D in infants and toddlers. J Clin Endocrinol Metab. 2008;93(7):2716–21. https://doi.org/10.1210/jc.2007-2790.CrossRefPubMedPubMedCentral

Trang HM, Cole DE, Rubin LA, Pierratos A, Siu S, Vieth R. Evidence that vitamin D3 increases serum 25-hydroxyvitamin D more efficiently than does vitamin D2. Am J Clin Nutr. 1998;68(4):854–8.CrossRef

Mazahery H, von Hurst PR. Factors affecting 25-hydroxyvitamin D concentration in response to vitamin D supplementation. Nutrients. 2015;7(7):5111–42. https://doi.org/10.3390/nu7075111.CrossRefPubMedPubMedCentral

10.

Hammami MM, Yusuf A. Differential effects of vitamin D2 and D3 supplements on 25-hydroxyvitamin D level are dose, sex, and time dependent: a randomized controlled trial. BMC Endocr Disord. 2017;17(1):12. https://doi.org/10.1186/s12902-017-0163-9. CrossRefPubMedPubMedCentral

11.

Tripkovic L, Lambert H, Hart K, Smith CP, Bucca G, Penson S, Chope G, Hyppönen E, Berry J, Vieth R, Lanham-New S. Comparison of vitamin D2 and vitamin D3 supplementation in raising serum 25-hydroxyvitamin D status: a systematic review and meta-analysis. Am J Clin Nutr. 2012;95(6):1357–64. https://doi.org/10.3945/ajcn.111.031070.CrossRefPubMedPubMedCentral

12.

Houghton LA, Vieth R. The case against ergocalciferol (vitamin D2) as a vitamin supplement. Am J Clin Nutr. 2006;84(4):694–7.CrossRef

13.

Romagnoli E, Mascia ML, Cipriani C, Fassino V, Mazzei F, D'Erasmo E, Carnevale V, Scillitani A, Minisola S. Short and long term variations in serum calciotropic hormones after single very large dose of ergocalciferol (vitamin D2) or cholecalciferol (vitamin D3) in the elderly. J Clin Endocrinol Metab. 2008;93:3015–20.CrossRef

14.

Nimitphong H, Saetung S, Chanprasertyotin S, Chailurkit LO, Ongphiphadhanakul B. Changes in circulating 25-hydroxyvitamin D according to vitamin D binding protein genotypes after vitamin D3 or D2 supplementation. Nutr J. 2013;12:39. https://doi.org/10.1186/1475-2891-12-39.CrossRefPubMedPubMedCentral

15.

Melhem SJ, Aiedeh KM, Hadidi KA. Effects of a 10-day course of a high dose calciferol versus a single mega dose of ergocalciferol in correcting vitamin D deficiency. Ann Saudi Med. 2015;35(1):13–8. https://doi.org/10.5144/0256-4947.2015.13.CrossRefPubMedPubMedCentral

16.

Demetriou ET, Travison TG, Holick MF. Treatment with 50,000 IU vitamin D₂ every other week and effect on serum 25-hydroxyvitamin D₂, 25-hydroxyvitamin D₃, and total 25-hydroxyvitamin D in a clinical setting. Endocr Pract. 2012;18(3):399–402. https://doi.org/10.4158/EP11268.OR.CrossRefPubMed

17.

Macdonald HM, Wood AD, Tang JCY, Fraser WD. Comparison of vitamin D2 and vitamin D3 supplementation in increasing serum 25-hydroxyvitamin D status: a systematic review and meta-analysis. Am J Clin Nutr. 2012;96(5):1152–3.CrossRef

18.

Cashman KD, Kiely M, Seamans KM, Urbain P. Effect of ultraviolet light–exposed mushrooms on vitamin D status: liquid chromatography–tandem mass spectrometry reanalysis of bio-banked sera from a randomized controlled trial and a systematic review plus meta-analysis. J Nutr. 2016;146(3):565–75.CrossRef

19.

Biancuzzo RM, Clarke N, Reitz RE, Travison TG, Holick MF. Serum concentrations of 1,25-dihydroxyvitamin D2 and 1,25-dihydroxyvitamin D3 in response to vitamin D2 and vitamin D3 supplementation. J Clin Endocrinol Metab. 2013;98(3):973–9. https://doi.org/10.1210/jc.2012-2114.CrossRefPubMedPubMedCentral

20.

Tjellesen L, Hummer L, Christiansen C, Rødbro P. Serum concentration of vitamin D metabolites during treatment with vitamin D2 and D3 in normal premenopausal women. Bone Miner. 1986;1(5):407–13.PubMed

21.

Mazahery H, Stonehouse W, von Hurst PR. The effect of monthly 50,000 IU or 100,000 IU vitamin D supplements on vitamin D status in premenopausal middle eastern women living in Auckland. Eur J Clin Nutr. 2015;69(3):367–72. https://doi.org/10.1038/ejcn.2014.264.CrossRefPubMed

22.

Waterhouse M, Tran B, Armstrong BK, Baxter C, Ebeling PR, English DR, Gebski V, Hill C, Kimlin MG, Lucas RM, Venn A, Webb PM, Whiteman DC, Neale RE. Environmental, personal, and genetic determinants of response to vitamin D supplementation in older adults. J Clin Endocrinol Metab. 2014;99(7):E1332–40. https://doi.org/10.1210/jc.2013-4101.CrossRefPubMed

23.

Aterrado S, Ono G, Kanehira-Mar S, Meier J, Swislocki A. Evaluating vitamin D repletion regimens and effects in veteran patients. Ann Pharmacother. 2015;49(9):969–77.CrossRef

24.

Gallagher JC, Yalamanchili V, Smith LM. The effect of vitamin D supplementation on serum 25(OH)D in thin and obese women. J Steroid Biochem Mol Biol. 2013;136:195–200. https://doi.org/10.1016/j.jsbmb.2012.12.003.CrossRefPubMed

25.

Ekwaru JP, Zwicker JD, Holick MF, Giovannucci E, Veugelers PJ. The importance of body weight for the dose response relationship of oral vitamin D supplementation and serum 25-hydroxyvitamin D in healthy volunteers. PLoS One 2014:5; 9(11):e111265. doi: https://doi.org/10.1371/journal.pone.0111265.

26.

Alvi SN, Yusuf A, Hammami MM. Simultaneous quantification of vitamin D-2, vitamin D-3, and their 25- hydroxy metabolites in human plasma by high performance liquid chromatography. J Bioequiv Availab. 2012;S14:1–5.CrossRef

27.

Randomization.com. Dallal GE. http://www.jerrydallal.com/random/assign.htm Accessed 13 Jan2019.

28.

Hymøller L, Jensen SK. Vitamin D₂ impairs utilization of vitamin D₃ in high-yielding dairy cows in a cross-over supplementation regimen. J Dairy Sci. 2011;94(7):3462–6. https://doi.org/10.3168/jds.2010-4111.CrossRefPubMed

29.

Saliba W, Barnett-Griness O, Rennert G. The relationship between obesity and the increase in serum 25(OH)D levels in response to vitamin D supplementation. Osteoporos Int. 2013;24(4):1447–54. https://doi.org/10.1007/s00198-012-2129-0.CrossRefPubMed

30.

Tepper S, Shahar DR, Geva D, Ish-Shalom S. Predictors of serum 25(oh)D increase following bimonthly supplementation with 100,000IU vitamin D in healthy, men aged 25-65 years. J Steroid Biochem Mol Biol. 2014;144 Pt A:163–6. https://doi.org/10.1016/j.jsbmb.2013.12.005.CrossRefPubMed

31.

Møller UK, við Streym S, Jensen LT, Mosekilde L, Schoenmakers I, Nigdikar S, Rejnmark L. Increased plasma concentrations of vitamin D metabolites and vitamin D binding protein in women using hormonal contraceptives: a cross-sectional study. Nutrients. 2013;5(9):3470–80. https://doi.org/10.3390/nu5093470.CrossRefPubMedPubMedCentral

32.

Mulligan GB, Licata A. Taking vitamin D with the largest meal improves absorption and results in higher serum levels of 25-hydroxyvitamin D. J Bone Miner Res. 2010;25(4):928–30. https://doi.org/10.1002/jbmr.67.CrossRefPubMed

Title: Vitamin-D2 treatment-associated decrease in 25(OH)D3 level is a reciprocal phenomenon: a randomized controlled trial
Authors: Muhammad M. Hammami
Kafa Abuhdeeb
Safa Hammami
Ahmed Yusuf
Publication date: 01-12-2019
Publisher: BioMed Central
Published in: BMC Endocrine Disorders / Issue 1/2019
Electronic ISSN: 1472-6823
DOI: https://doi.org/10.1186/s12902-019-0337-8

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Vitamin-D2 treatment-associated decrease in 25(OH)D3 level is a reciprocal phenomenon: a randomized controlled trial

Abstract

Background

Methods

Results

Conclusions

Trial registration

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Trial registration

Please log in to get access to this content

Other articles of this Issue 1/2019

Factors associated with glycemic control in community-dwelling elderly individuals with type 2 diabetes mellitus in Zhejiang, China: a cross-sectional study

Patterns and trends of utilization of incretin-based medicines between 2008 and 2014 in three Italian geographic areas

The association of circulating irisin with metabolic risk factors in Chinese adults: a cross-sectional community-based study

The role of the adipocytokines vaspin and visfatin in vascular endothelial function and insulin resistance in obese children

Barriers and facilitators to weight management in overweight and obese women living in Australia with PCOS: a qualitative study

The precursor for nerve growth factor (proNGF) is not a serum or biopsy-rinse biomarker for thyroid cancer diagnosis

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page